While current asthma guidelines including the Global Initiative for Asthma strategy offer guidance on patient characteristics that predict optimal response to anti-interleukin (IL)-5 and anti-IL-5 receptor α (anti-IL-5Rα) biologics, they do not provide any information specifically addressing patients with SEA and PAO [1]. The gene discussed is IL5; the disease is asthma.